Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Pooled Efficacy and Safety of Teclistamab in 217 Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from 3 Registrational Clinical Studies

Blood (2024) 144 (Supplement 1): 3331.

https://doi.org/10.1182/blood-2024-200354

Published: 2024

Journal Articles

Efficacy and Safety of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Japanese Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 Monumental-1 Study

Shigeki Ito, Yoshiaki Kuroda, Kazutaka Sunami, Kosei Matsue, Kazunori Imada, Hideto Tamura, Mikihiro Takamoto, Hiroshi Yamazaki, Ei Fujikawa, Lixia Pei, Tara J Masterson, Michela Campagna, Bonnie W Lau, Yasushi Takamatsu

Blood (2024) 144 (Supplement 1): 7011.

https://doi.org/10.1182/blood-2024-199663

Published: 2024

Journal Articles

Successful MPB Therapy Followed By Bortezomib Maintenance for Non-Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma: Japanese Phase 2 Study - Broad-J Study

Blood (2017) 130 (Supplement 1): 5432.

https://doi.org/10.1182/blood.V130.Suppl_1.5432.5432

Published: 2017

Journal Articles

A New Prognostic Scoring System for Multiple Myeloma in the Era of Novel Agents and Autologous Stem Cell Transplantation: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Shuji Ozaki, MD PhD, Takayuki Saitoh, MD PhD, Hiroshi Handa, MD PhD, Kenshi Suzuki, MD PhD, Naoki Takezako, MD PhD, Kazutaka Sunami, MD, Yoshiaki Kuroda, MD, Mitsuhiro Itagaki, MD, Hideki Asaoku, MD, Eiichi Nagura, MD, Shimizu Kazuyuki, MD, Hirokazu Murakami, MD PhD

Blood (2016) 128 (22): 4436.

https://doi.org/10.1182/blood.V128.22.4436.4436

Published: 2016

Journal Articles

A Revised International Staging System of Multiple Myeloma in the Era of Novel Agents and Autologous Stem Cell Transplantation in Japan: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Shuji Ozaki, MD PhD, Takayuki Saitoh, MD PhD, Hiroshi Handa, MD PhD, Hirokazu Murakami, MD, Kenshi Suzuki, Naoki Takezako, MD PhD, Jun Konishi, Kazutaka Sunami, Yoshiaki Kuroda, Mitsuhiro Itagaki, MD, Hideki Asaoku, MD, Eiichi Nagura, MD, Kazuyuki Shimizu, MD

Blood (2015) 126 (23): 4199.

https://doi.org/10.1182/blood.V126.23.4199.4199

Published: 2015

Journal Articles

MM-011: A Phase 2 Study of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma in Japan

Shotaro Hagiwara, Shinichiro Okamoto, Kosei Matsue, Shinsuke Iida, Kazutaka Sunami, Takuya Komeno, Kenshi Suzuki, Kiyoshi Ando, Masafumi Taniwaki, Kensei Tobinai, MD PhD, Takaaki Chou, Hitomi Kaneko, Hiromi Iwasaki, MD PhD, Chie Uemura, Hiromi Tamakoshi, Mohamed H Zaki, Thomas Doerr, Yoshiaki Kuroda, Tatsuo Ichinohe, MDPhD

Blood (2015) 126 (23): 5374.

https://doi.org/10.1182/blood.V126.23.5374.5374

Published: 2015

Journal Articles

Chromosomal Translocation (14;16)-Positive Multiple Myeloma Shows Negativity for CD56 Expression and Unfavorable Outcome Even in the Era of Novel Drugs

Blood (2014) 124 (21): 3349.

https://doi.org/10.1182/blood.V124.21.3349.3349

Published: 2014

Journal Articles

Survival of Multiple Myeloma Patients in the Era of Novel Agents and Autologous Stem Cell Transplantation: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Shuji Ozaki, Hiroshi Handa, MD PhD, Takayuki Saitoh, MD, PhD, Hirokazu Murakami, MD, PhD, Mitsuhiro Itagaki, MD, Hideki Asaoku, MD, Kenshi Suzuki, MD PhD, Atsushi Isoda, MD PhD, Morio Sawamura, MD PhD, Jun Konishi, MD, Kazutaka Sunami, Naoki Takezako, MD PhD, Shotaro Hagiwara, MD PhD, Yoshiaki Kuroda, MD PhD, Takaaki Chou, Eiko Shibata, Kazuyuki Shimizu, MD, Eiichi Nagura, MD

Blood (2014) 124 (21): 5684.

https://doi.org/10.1182/blood.V124.21.5684.5684

Published: 2014

Journal Articles

Novel Agents and Autologous Stem Cell Transplantation Improve Survival of Multiple Myeloma Patients with Ages 65–70 Years: A Multicenter Retrospective Collaborative Study Between Japanese Society of Myeloma and European Myeloma Network

Shuji Ozaki, MD, PhD, Takeshi Harada, MD, Takayuki Saitoh, M.D. Ph.D., Chihiro Shimazaki, MD, PhD, Mitsuhiro Itagaki, MD, Hideki Asaoku, MD, Yoshiaki Kuroda, MD, PhD, Takaaki Chou, MD, PhD, Yumiko Yoshiki, MD, Kenshi Suzuki, MD, PhD, Hirokazu Murakami, M.D., Ph.D., Kunihiko Hayashi, PhD, Antonio Palumbo, MD, Kazuyuki Shimizu, MD

Blood (2012) 120 (21): 5030.

https://doi.org/10.1182/blood.V120.21.5030.5030

Published: 2012

Journal Articles

T-Cell Immunotherapy with a Chimeric Receptor Against CD38 Is Effective in Eliminating Myeloma Cells

Keichiro Mihara, MD, PhD, Joyeeta Bhattacharyya, MD, PhD, Akira Kitanaka, MD, PhD, Akihiro Ihara, MD, PhD, Akira Sakai, MD, PhD, Yoshiaki Kuroda, MD, PhD, Hideki Asaoku, MD, Yoshihiro Takihara, MD, PhD, Akiro Kimura, MD

Blood (2011) 118 (21): 885.

https://doi.org/10.1182/blood.V118.21.885.885

Published: 2011

Journal Articles

Cyclin D1 Overexpression Increases Chemosensitivity Via Prolonged S-Phase and TRAIL Signal in Myeloma Cell.

Yoshiaki Kuroda, MD, Akira Sakai, M.D., Naohiro Tsuyama, Ph.D., Yuta Katayama, M.D., Shoso Munemasa, M.D., Yoshiko Okikawa, M.D., Hideki Asaoku, M.D., Nanae Nakaju, Mami Mizuno, Takashi Nishizaka, M.D., Katsunari Ogawa, Hideo Tanaka, M.D., Akiro Kimura, M.D.

Blood (2007) 110 (11): 3530.

https://doi.org/10.1182/blood.V110.11.3530.3530

Published: 2007

Journal Articles

Immunomodulatory Thalidomide Analogs Do Not Affect Osteoprogenitor Differentiation and Low Concentration of Bortezomib Promotes It, While Both Agents Suppress Osteoclast Differentiation.

Shoso Munemasa, MD, Akira Sakai, M.D., Yoshiaki Kuroda, M.D., Yoshiko Okikawa, M.D., Yuta Katayama, M.D., Hideki Asaoku, M.D., Tadahiko Kubo, M.D., Shoji Shimose, M.D., Akiro Kimura, M.D.

Blood (2007) 110 (11): 4780.

https://doi.org/10.1182/blood.V110.11.4780.4780

Published: 2007

Journal Articles

Cyclin D1 Overexpression Increases Chemosensitivity Via the Induction of Bim in Myeloma Cells.

Yoshiaki Kuroda, MD, Akira Sakai, M.D., Naohiro Tsuyama, Ph.D., Shoso Munemasa, M.D., Nanae Nakaju, Mami Mizuno, Yoshiko Okikawa, M.D., Yuta Katayama, M.D., Akiro Kimura, M.D.

Blood (2006) 108 (11): 3418.

https://doi.org/10.1182/blood.V108.11.3418.3418

Published: 2006

Journal Articles

Connective Tissue Growth Factor (CTGF) Is an Indicator of Bone Involvement in Multiple Myeloma.

Shoso Munemasa, MD, Akira Sakai, M.D., Yoshiaki Kuroda, M.D., Yoshiko Okikawa, M.D., Yuta Katayama, M.D., Hideki Asaoku, M.D., Tadahiko Kubo, M.D., Noelynn Oliver, Ph.D., Akiro Kimura, M.D.

Blood (2006) 108 (11): 5025.

https://doi.org/10.1182/blood.V108.11.5025.5025

Published: 2006

Journal Articles

Induction of Cyclin D1 Gene in Myeloma Cells Down-Regulates the Expression of Cyclin D2.

Yoshiaki Kuroda, MD, Akira Sakai, MD, Naohiro Tsuyama, PhD, Mami Mizuno, Nanae Nakaju, Shoso Munemasa, MD, Yoshiko Okikawa, MD, Yuta Katayama, MD, Akiro Kimura, MD

Blood (2005) 106 (11): 3411.

https://doi.org/10.1182/blood.V106.11.3411.3411

Published: 2005

Journal Articles

What Is Important Factor of Bone Disease in Multiple Myeloma?.

Shoso Munemasa, M.D., Akira Sakai, M.D., Yoshiko Okikawa, M.D., Yoshiaki Kuroda, M.D., Yuta Katayama, M.D., Hideki Asaoku, M.D., Akiro Kimura, M.D.

Blood (2004) 104 (11): 4855.

https://doi.org/10.1182/blood.V104.11.4855.4855

Published: 2004

Journal Articles

The Reason Why High-Dose Melphalan Followed by Autologous Stem-Cell Transplantation Produces Good Response in Multiple Myeloma.

Yoshiaki Kuroda, M.D., Akira Sakai, M.D., Yoshiko Okikawa, M.D., Shoso Munemasa, M.D., Yuta Katayama, M.D., Yasuo Takimoto, M.D., Hajime Okita, M.D., Akiro Kimura, M.D.

Blood (2004) 104 (11): 5201.

https://doi.org/10.1182/blood.V104.11.5201.5201

Published: 2004

NARROW

Pooled Efficacy and Safety of Teclistamab in 217 Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from 3 Registrational Clinical Studies

Efficacy and Safety of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Japanese Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 Monumental-1 Study

Successful MPB Therapy Followed By Bortezomib Maintenance for Non-Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma: Japanese Phase 2 Study - Broad-J Study

A New Prognostic Scoring System for Multiple Myeloma in the Era of Novel Agents and Autologous Stem Cell Transplantation: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

A Revised International Staging System of Multiple Myeloma in the Era of Novel Agents and Autologous Stem Cell Transplantation in Japan: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

MM-011: A Phase 2 Study of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma in Japan

Chromosomal Translocation (14;16)-Positive Multiple Myeloma Shows Negativity for CD56 Expression and Unfavorable Outcome Even in the Era of Novel Drugs

Survival of Multiple Myeloma Patients in the Era of Novel Agents and Autologous Stem Cell Transplantation: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Novel Agents and Autologous Stem Cell Transplantation Improve Survival of Multiple Myeloma Patients with Ages 65–70 Years: A Multicenter Retrospective Collaborative Study Between Japanese Society of Myeloma and European Myeloma Network

T-Cell Immunotherapy with a Chimeric Receptor Against CD38 Is Effective in Eliminating Myeloma Cells

Cyclin D1 Overexpression Increases Chemosensitivity Via Prolonged S-Phase and TRAIL Signal in Myeloma Cell.

Immunomodulatory Thalidomide Analogs Do Not Affect Osteoprogenitor Differentiation and Low Concentration of Bortezomib Promotes It, While Both Agents Suppress Osteoclast Differentiation.

Cyclin D1 Overexpression Increases Chemosensitivity Via the Induction of Bim in Myeloma Cells.

Connective Tissue Growth Factor (CTGF) Is an Indicator of Bone Involvement in Multiple Myeloma.

Induction of Cyclin D1 Gene in Myeloma Cells Down-Regulates the Expression of Cyclin D2.

What Is Important Factor of Bone Disease in Multiple Myeloma?.

The Reason Why High-Dose Melphalan Followed by Autologous Stem-Cell Transplantation Produces Good Response in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only